Depomed

Depomed, Inc. is an international pharmaceutical company, which mainly develops products for treatment in neurology, pain and diseases of the central nervous system.^[2] The company is a publicly traded company on NASDAQ under the symbol "DEPO", with several products approved and recognized by the U.S. Food and Drug Administration (FDA).

Products

The company's products include Glumetza, Gralise, Serada and DM-1992, which mainly focus on neurology and central nervous system diseases.^[3]

For postherpetic neuralgia

In Jan 2011, the company's product, Gralise (gabapentin) was approved by the US FDA for the treatment of postherpetic neuralgia, which was the 3rd approval of FDA for Depomed products.^[4] The drug has also received Orphan Drug designation from the FDA.

For diabetes and others

The company's another treatment, the metformin hydrochloride extended release tablets Glumetza, was also approved for treatment with diabetes type II in adults, and is mainly sold in the US.^[5]

Corporate affairs

Acquisition

In June 2012, all rights to Zipsor Liquid Filled Capsules was acquired by Depomed, Inc. from Xanodyne Pharmaceuticals, Inc., the revenue of the latter was approximately $19 million as within the twelve months from Jun 2011 to May 2012.^[6]

Lawsuits

In March 2012, the company filed a patent infringement lawsuit against three companies that had filed Abbreviated New Drug Applications with the US FDA, claiming infringement of Depomed's six US patents listed for Gralise in the FDA's Orange Book.^[7]

References

External links

• Company homepage